Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PSEUDO-12 vs ACTIFED
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Decongestant; acts on alpha-adrenergic receptors in the nasal mucosa to produce vasoconstriction, reducing edema and nasal congestion.
ACTIFED contains triprolidine, a first-generation antihistamine that competitively inhibits histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
FDA: Temporary relief of nasal congestion due to colds, allergies, or sinusitis,Off-label: Adjunct in otitis media, eustachian tube dysfunction
Temporary relief of symptoms associated with allergic rhinitis (sneezing, rhinorrhea, pruritus),Temporary relief of nasal congestion due to common cold, hay fever, or other upper respiratory allergies
60 mg orally every 4 to 6 hours as needed; maximum 240 mg per day.
1 tablet (pseudoephedrine HCl 60 mg, triprolidine HCl 2.5 mg) orally every 4-6 hours; maximum 4 tablets in 24 hours.
Terminal elimination half-life: 4-6 hours (adults); 6-8 hours (children); prolonged in renal impairment (up to 20 hours in severe disease).
Triprolidine: 3.2 hours; Pseudoephedrine: 5–8 hours (p H-dependent: alkaline urine prolongs). Terminal half-life for clinical use typically 4–6 hours.
Hepatic metabolism via N-demethylation (CYP3A4) and glucuronidation; minor renal excretion as unchanged drug.
Triprolidine: Hepatic metabolism via CYP450 enzymes. Pseudoephedrine: Partially metabolized in liver by N-demethylation; excreted unchanged in urine (70-90%).
Renal: 70-90% as unchanged drug; biliary/fecal: <10%
Renal: 80% (20% unchanged, 60% as metabolites). Fecal: 20% (unchanged and metabolites). Active tubular secretion of pseudoephedrine.
Binding: 30-40%; primarily to albumin.
Triprolidine: 60% bound to serum albumin; Pseudoephedrine: 20–30% bound to plasma proteins (mainly albumin).
Vd: 2.6-3.5 L/kg; indicates extensive tissue distribution (e.g., lungs, liver, kidney).
Triprolidine: 2.5–4.0 L/kg; Pseudoephedrine: 2.6–3.5 L/kg. Indicates extensive tissue distribution.
Oral: 90-100% (immediate-release); 80-90% (extended-release).
Oral: Triprolidine 90–100%; Pseudoephedrine 100% (first-pass metabolism negligible).
e GFR 30-50 m L/min: 30 mg every 6 hours as needed; maximum 120 mg/day. e GFR <30 m L/min: 30 mg every 12 hours as needed; maximum 60 mg/day.
Cr Cl 30-50 m L/min: extend dosing interval to every 8 hours. Cr Cl 15-29 m L/min: every 12 hours. Cr Cl <15 m L/min: not recommended.
Child-Pugh A: no adjustment. Child-Pugh B: 30 mg every 6 hours as needed; maximum 120 mg/day. Child-Pugh C: use is not recommended.
Child-Pugh A: no adjustment. Child-Pugh B: consider extending interval to every 8 hours. Child-Pugh C: avoid use.
Children 6-12 years: 30 mg orally every 4-6 hours; maximum 120 mg/day. Children 12-17 years: same as adult dosing.
Children 6-12 years: 1/2 tablet (pseudoephedrine 30 mg, triprolidine 1.25 mg) orally every 6 hours; max 2 tablets/24 hours. Children <6 years: not recommended.
Initiate at 30 mg every 6 hours as needed; maximum 120 mg/day due to increased sensitivity and higher risk of adverse effects.
Start with 1/2 tablet (pseudoephedrine 30 mg, triprolidine 1.25 mg) orally every 8 hours; monitor for CNS excitation and anticholinergic effects.
None.
None.
Cardiovascular effects: hypertension, palpitations, arrhythmias; CNS stimulation: insomnia, anxiety, tremor; exacerbation of glaucoma, hyperthyroidism, diabetes; urinary retention in prostatic hypertrophy; rebound congestion with prolonged use.
Cardiovascular effects: hypertension, palpitations, tachycardia, arrhythmias,CNS stimulation: nervousness, dizziness, insomnia, especially in elderly,May cause urinary retention in patients with prostatic hypertrophy,Use caution in patients with diabetes, hyperthyroidism, ischemic heart disease, increased intraocular pressure,Anticholinergic effects: dry mouth, blurred vision, constipation
Severe hypertension, coronary artery disease, concurrent MAO inhibitor therapy, narrow-angle glaucoma, urinary retention, hypersensitivity to sympathomimetics.
Hypersensitivity to triprolidine, pseudoephedrine, or any component,Severe hypertension or coronary artery disease,Monoamine oxidase inhibitor (MAOI) therapy (concurrent or within 14 days),Narrow-angle glaucoma,Urinary retention,During or within 14 days of MAOI use
Avoid high-tyramine foods (e.g., aged cheeses, cured meats, fermented products) if taking MAOIs concurrently. Limit caffeine-containing beverages as they may increase CNS stimulation.
Avoid high-tyramine foods (aged cheese, cured meats, fermented products) as pseudoephedrine may potentiate vasopressor effects. Grapefruit juice may decrease pseudoephedrine absorption; separate administration by at least 4 hours.
FDA Pregnancy Category C. First trimester: no evidence of structural teratogenicity in human studies but avoid due to potential vasoconstriction. Second/third trimester: risk of fetal tachycardia, decreased placental perfusion, and potential for maternal hypertension; prolonged use may cause fetal hypoxia.
FDA Pregnancy Category C. First trimester: Limited human data; animal studies show fetal toxicity at high doses. Avoid unless benefit outweighs risk. Second/third trimesters: Risk of premature labor, neonatal respiratory depression, and withdrawal symptoms with prolonged use. Use lowest effective dose for shortest duration.
Excreted into breast milk in low amounts (M/P ratio ~0.5). Considered safe at recommended doses; however, monitor infant for irritability or insomnia.
Pseudoephedrine is excreted into breast milk; M/P ratio approximately 3.5. Triprolidine is present in milk. Potential for irritability, sleep disturbance in infants; may reduce milk supply. Use with caution; alternative preferred. Discontinue breastfeeding or drug based on necessity.
No specific dose adjustment required; however, use lowest effective dose for shortest duration due to physiologic changes (increased renal clearance may slightly reduce plasma levels).
No specific dose adjustment recommended for pregnancy; however, increased plasma volume may reduce drug concentrations. Use lowest effective dose due to limited safety data. Avoid in hypertension or preeclampsia.
Pseudoephedrine is a sympathomimetic amine used as a decongestant. It is contraindicated in severe hypertension, coronary artery disease, and concurrent MAOI use. Monitor for CNS stimulation, insomnia, and elevated blood pressure. Extended-release formulations should not be crushed or chewed.
Actifed (pseudoephedrine + triprolidine) is contraindicated in patients with severe hypertension, coronary artery disease, or narrow-angle glaucoma. Pseudoephedrine can cause CNS stimulation and insomnia, so avoid evening dosing. Triprolidine is a first-generation antihistamine with significant anticholinergic effects; use caution in elderly or those with BPH, urinary retention, or asthma.
Do not use if you have high blood pressure or heart disease unless directed by a doctor.,Avoid taking within 4 hours of bedtime to prevent insomnia.,Do not crush or chew extended-release tablets.,Limit caffeine intake while taking this medication.,Stop use and consult a doctor if symptoms persist after 7 days.
Do not take with other cold or allergy medications containing decongestants or antihistamines.,Avoid alcohol and sedatives as they may increase drowsiness.,Do not crush or chew extended-release tablets; swallow whole.,Monitor for increased blood pressure or heart rate; discontinue if palpitations occur.,May cause dizziness; avoid driving or operating heavy machinery until you know how it affects you.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PSEUDO-12 vs ACTIFED, answered by our medical review team.
PSEUDO-12 is a Decongestant that works by Decongestant; acts on alpha-adrenergic receptors in the nasal mucosa to produce vasoconstriction, reducing edema and nasal congestion.. ACTIFED is a Decongestant/Antihistamine Combination that works by ACTIFED contains triprolidine, a first-generation antihistamine that competitively inhibits histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PSEUDO-12 and ACTIFED depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PSEUDO-12 is: 60 mg orally every 4 to 6 hours as needed; maximum 240 mg per day.. The standard adult dose of ACTIFED is: 1 tablet (pseudoephedrine HCl 60 mg, triprolidine HCl 2.5 mg) orally every 4-6 hours; maximum 4 tablets in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PSEUDO-12 and ACTIFED in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PSEUDO-12 is classified as Category C. FDA Pregnancy Category C. First trimester: no evidence of structural teratogenicity in human studies but avoid due to potential vasoconstriction. Second/third trimester: risk of fe. ACTIFED is classified as Category C. FDA Pregnancy Category C. First trimester: Limited human data; animal studies show fetal toxicity at high doses. Avoid unless benefit outweighs risk. Second/third trimesters: Risk . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.